Entasis Therapeutics Holdings Inc - ESG Rating & Company Profile powered by AI
Other corporations in the rating industry group for Entasis Therapeutics Holdings Inc are shownin the table. The analysis of Entasis Therapeutics Holdings Inc is prepared by All Street Sevva using leading AI. If you are employed by Entasis Therapeutics Holdings Inc and you would like to licence your Sustainability aseessment, please contact us.
Entasis Therapeutics Holdings Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.4; made up of an environmental score of 5.3, social score of 0.0 and governance score of 2.0.
2.4
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1499 | Verici Dx Plc | 2.5 | Medium |
1499 | Verve Therapeutics Inc | 2.5 | Medium |
1512 | Entasis Therapeutics Holdings Inc | 2.4 | Medium |
1512 | CEL-SCI Corp | 2.4 | Medium |
1512 | Allena Pharmaceuticals Inc | 2.4 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Entasis Therapeutics Holdings Inc have an accelerator or VC vehicle to help deliver innovation?
Does Entasis Therapeutics Holdings Inc disclose current and historical energy intensity?
Does Entasis Therapeutics Holdings Inc report the average age of the workforce?
Does Entasis Therapeutics Holdings Inc reference operational or capital allocation in relation to climate change?
Does Entasis Therapeutics Holdings Inc disclose its ethnicity pay gap?
Does Entasis Therapeutics Holdings Inc disclose cybersecurity risks?
Does Entasis Therapeutics Holdings Inc offer flexible work?
Does Entasis Therapeutics Holdings Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Entasis Therapeutics Holdings Inc disclose the number of employees in R&D functions?
Does Entasis Therapeutics Holdings Inc conduct supply chain audits?
Does Entasis Therapeutics Holdings Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Entasis Therapeutics Holdings Inc conduct 360 degree staff reviews?
Does Entasis Therapeutics Holdings Inc disclose the individual responsible for D&I?
Does Entasis Therapeutics Holdings Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Entasis Therapeutics Holdings Inc disclose current and / or historical scope 2 emissions?
Does Entasis Therapeutics Holdings Inc disclose water use targets?
Does Entasis Therapeutics Holdings Inc have careers partnerships with academic institutions?
Did Entasis Therapeutics Holdings Inc have a product recall in the last two years?
Does Entasis Therapeutics Holdings Inc disclose incidents of discrimination?
Does Entasis Therapeutics Holdings Inc allow for Work Councils/Collective Agreements to be formed?
Has Entasis Therapeutics Holdings Inc issued a profit warning in the past 24 months?
Does Entasis Therapeutics Holdings Inc disclose parental leave metrics?
Does Entasis Therapeutics Holdings Inc disclose climate scenario or pathway analysis?
Does Entasis Therapeutics Holdings Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Entasis Therapeutics Holdings Inc disclose the pay ratio of women to men?
Does Entasis Therapeutics Holdings Inc support suppliers with sustainability related research and development?
Does Entasis Therapeutics Holdings Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Entasis Therapeutics Holdings Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Entasis Therapeutics Holdings Inc involved in embryonic stem cell research?
Does Entasis Therapeutics Holdings Inc disclose GHG and Air Emissions intensity?
Does Entasis Therapeutics Holdings Inc disclose its waste policy?
Does Entasis Therapeutics Holdings Inc report according to TCFD requirements?
Does Entasis Therapeutics Holdings Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Entasis Therapeutics Holdings Inc disclose energy use targets?
Does Entasis Therapeutics Holdings Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Entasis Therapeutics Holdings Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Entasis Therapeutics Holdings Inc
These potential risks are based on the size, segment and geographies of the company.
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts.